Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
New Approaches Promise to Improve Local Ewing Sarcoma Results
Ian J. Cohen
*
,
Shifra Ash
*
Corresponding author for this work
Clinical Departments
Schneider Childrens Medical Center Israel
Ruth Rappaport Children's Hospital
Technion-Israel Institute of Technology
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New Approaches Promise to Improve Local Ewing Sarcoma Results'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ewing Sarcoma
100%
High Risk
66%
CD56
66%
Group by
33%
Chemotherapy
33%
Consecutive Patients
33%
Tumor Cells
33%
Initial Treatment
33%
Low-risk Group
33%
Patient's Will
33%
Clinical High Risk
33%
Progression-free Survival
33%
Lack of Response
33%
Patient-independent
33%
Busulfan
33%
Melphalan
33%
Autologous Stem Cell Rescue
33%
Relapse Pattern
33%
Busulfan Conditioning
33%
Melphalan Conditioning
33%
Medicine and Dentistry
Ewing Sarcoma
100%
Melphalan
66%
Busulfan
66%
Conditioning
33%
Stem Cell
33%
Tumor Cell
33%
Low Risk Population
33%
Emergency Medical Technician
33%
Progression Free Survival
33%
Pharmacology, Toxicology and Pharmaceutical Science
Ewing Sarcoma
100%
Chemotherapy
66%
Busulfan
66%
Melphalan
66%
Neoplasm
33%
Progression Free Survival
33%
Neuroscience
Busulfan
100%
Melphalan
100%
Stem Cell
50%